Premium
Oncologic outcomes of transoral robotic surgery for HPV ‐negative oropharyngeal carcinomas
Author(s) -
Parhar Harman S.,
Weinstein Gregory S.,
O'Malley Bert W.,
Shimunov David,
Rassekh Christopher H.,
Chalian Ara A.,
Newman Jason G.,
Basu Devraj,
Cannady Steven B.,
Rajasekaran Karthik,
Lin Alexander,
Lukens John N.,
SwisherMcClure Samuel,
Cohen Roger B.,
Bauml Joshua M.,
Aggrawal Charu,
Brody Robert M.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26776
Subject(s) - medicine , transoral robotic surgery , interquartile range , perioperative , neck dissection , surgery , chemoradiotherapy , stage (stratigraphy) , retrospective cohort study , radiation therapy , adjuvant , oncology , carcinoma , paleontology , biology
Background Patients with human papillomavirus (HPV)‐negative oropharyngeal squamous cell carcinoma (OPSCC) continue to experience disappointing outcomes following chemoradiotherapy (CRT) and appreciable morbidity following historical surgical approaches. We aimed to investigate the oncologic outcomes and perioperative morbidity of a transoral robotic surgery (TORS) approach to surgically resectable HPV‐negative OPSCC. Methods Retrospective analysis HPV‐negative OPSCC patients who underwent TORS, neck dissection and pathology‐guided adjuvant therapy (2005–2017). Results Fifty‐six patients (91.1% stage III/IV) were included. Three‐year overall survival, locoregional control, and disease‐free survival were 85.5%, 84.4%, and 73.6%, respectively (median follow‐up 30.6 months, interquartile range 18.4–66.6). Eighteen (32.1%) patients underwent adjuvant radiotherapy and 20 (39.3%) underwent adjuvant CRT. Perioperative mortality occurred in one (1.8%) patient and hemorrhage occurred in two (3.6%) patients. Long‐term gastrostomy and tracheostomy rates were 5.4% and 0.0%, respectively. Conclusion The TORS approach for resectable HPV‐negative OPSCC can achieve encouraging oncologic outcomes with infrequent morbidity.